← Leaderboards
Andrew Stephen Hollands
Inhibrx, Inc.
$1,448,556
Attributed
$1,448,556
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$1,448,556 · 2
By mechanism
R44$1,224,154 · 1
R43$224,402 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Recruitment Activity”
- Valerie Koch · University Corporation For Atmospheric Res$243,972,016
- Prasant Mohapatra · University Of California At Davis$39,700,992
- Michael P Harms · Washington University$13,645,932
- Mark Brian Reed · San Diego State University$13,246,314
- Ki Young Chung · Prisma Health - Upstate$9,859,012
- Deborah Bunin · Sri International$8,836,822
Research focus
Recruitment ActivitySpecificityInfectionProteinsSiteAlpha CellHumanized AntibodyImmuneIn VitroNovel TherapeuticsFc DomainResistance DevelopmentCellsCell SurfaceBacteriaAntibiotic ResistanceBaseIgg1BindingEpitopesIn VivoLeadAntibodiesTherapeutic Antibodies
Grant awards (5)
Development of multispecific antibodies for the treatment of Pseudomonas aeruginosa infection$936,939
R44 · FY2017 · AI · contact PI
Development of multispecific antibodies for the treatment of Pseudomonas aeruginosa infection$223,854
R44 · FY2017 · AI · contact PI
Development of Multispecific Antibodies for the treatment of Methicillin Resistant Staphylococcus âaureus (MRSA) infection$116,006
R43 · FY2017 · AI · contact PI
Development of Multispecific Antibodies for the treatment of Methicillin Resistant Staphylococcus âaureus (MRSA) infection$108,396
R43 · FY2017 · AI · contact PI
Development of multispecific antibodies for the treatment of Pseudomonas aeruginosa infection$63,361
R44 · FY2017 · AI · contact PI